Pathology
病理
基本信息
- 批准号:7645866
- 负责人:
- 金额:$ 22.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AppearanceBioinformaticsClinicalDataDatabasesDevelopmentDoctor of MedicineEnsureEvaluationFreezingHistologicImage AnalysisIn Situ HybridizationIndividualKnock-outLaboratoriesMemorial Sloan-Kettering Cancer CenterMusNecrosisNormal tissue morphologyOperative Surgical ProceduresPathologicPathologyProcessProtocols documentationResearchResearch Ethics CommitteesResearch InfrastructureResearch PersonnelResectedResourcesServicesSlideSpecimenSurgical marginsSystemTissue MicroarrayTissue SampleTissuesTransgenic ModelXenograft procedurebasecellular imagingcost effectivedesignhuman tissuein vivoinhibitor/antagonistmolecular pathologymouse modelneoplasticpre-clinicalprogramsresearch studyresponsesarcomatissue processingtumorvalidation studies
项目摘要
The Pathology Core is designed to provide the investigators of the Program Project with expert
pathologic evaluation of all soft tissue sarcomas (STS) that present to Memorial Sloan-Kettering Cancer
Center. The Core will provide a centralized, comprehensive facility for tissue-based research. The resource will
provide tissues and associated data in an equitable and ethical manner, provide professional expertise in
histo- and molecular pathology and assist and perform tissue-based experimentation. The human tissues
used for research studies are obtained under existing IRB-approved protocols. The specific aims are:
1. To provide consistent, expert pathologic characterization of all STS specimens resected at MSKCC,
including a description of gross appearance, histologic type, tumor grade, necrosis, and surgical margins.
2. To supervise the procurement of normal and neoplastic human tissue samples and maintain a bank of
frozen sarcoma tissue for special studies conducted under the different projects. This process ensures that
adequate amounts of correctly identified and processed tissue reach the appropriate laboratories.
3. To provide expert histologic review for individual projects, including tumor viability and assessment of
tumor response to various investigational agents used in different studies, either in post-treated surgical
specimens or xenografts. Histologic response assessment to various inhibitors will also be provided for the
preclinical in vivo mouse models, as well as histologic expertise for the murine knockout/transgenic models .
4. To assist in performing high-throughput tissue microarray (TMA) and interpreting immunohistochemical
(IHC) and in situ hybridization studies (ISH) for validation studies of various microarray projects. An ATA-27
Beecher Automated tissue arrayer will be used to construct TMAs of varying sarcoma types and
accompanying normal tissues. Quantitative image analysis of the IHC/ISH results will be performed using an
ACIS II (automated cellular imaging system) Chromavision slide scanner tissue arrayer. Assistance with the
development of the Clinical Tissue Microarray (ClinTMA) Database by the Bioinformatics Core will be
provided, and results will be entered into this database as continuous values.
These aims offer a substantial infrastructure to the STS Program Project and allows Core B to provide the
required services in a cost effective manner.
病理核心旨在为该计划项目的调查人员提供专家
所有软组织肉瘤(STS)的病理评估,这些肉瘤(STS)存在于纪念斯隆 - 凯特癌癌症
中心。核心将为基于组织的研究提供集中的,全面的设施。资源将
以公平和道德的方式提供组织和相关数据,提供专业知识
组织和分子病理学,并协助并进行基于组织的实验。人体组织
用于研究的研究是根据现有IRB批准的协议获得的。具体目的是:
1。为了提供一致的专家病理学表征,对MSKCC上切除的所有STS标本
包括描述总外观,组织学类型,肿瘤等级,坏死和手术边缘。
2。监督正常和肿瘤的人体组织样本的采购,并保持
在不同项目下进行的肉瘤组织进行的肉瘤组织进行特殊研究。这个过程确保了
足够的正确识别和处理的组织到达适当的实验室。
3。为单个项目提供专家组织学审查,包括肿瘤的生存能力和评估
肿瘤对不同研究中使用的各种研究剂的反应,要么在治疗后的手术中
标本或异种移植物。还将为各种抑制剂提供组织学反应评估
临床前小鼠模型以及鼠敲除/转基因模型的组织学专业知识。
4。协助执行高通量组织微阵列(TMA)并解释免疫组织化学
(IHC)和原位杂交研究(ISH),用于对各种微阵列项目的验证研究。 ATA-27
Beecher自动组织阵列将用于构建不同类型的TMA和
伴随正常组织。 IHC/ISH结果的定量图像分析将使用
ACIS II(自动细胞成像系统)Chromavision幻灯片扫描仪阵列。协助
生物信息学核心的临床组织微阵列(Clintma)数据库的开发将是
提供的结果将作为连续值输入该数据库。
这些目标为STS计划项目提供了实质性的基础架构,并允许Core B提供
以经济有效的方式需要服务。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRISTINA R ANTONESCU其他文献
CRISTINA R ANTONESCU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRISTINA R ANTONESCU', 18)}}的其他基金
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10932621 - 财政年份:2023
- 资助金额:
$ 22.3万 - 项目类别:
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10468962 - 财政年份:2018
- 资助金额:
$ 22.3万 - 项目类别:
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10016095 - 财政年份:2018
- 资助金额:
$ 22.3万 - 项目类别:
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10247696 - 财政年份:2018
- 资助金额:
$ 22.3万 - 项目类别:
P1 - Molecular Mechanisms of KIT Signaling and Imatinib Resistance in GIST
P1 - GIST 中 KIT 信号传导和伊马替尼耐药的分子机制
- 批准号:
7976097 - 财政年份:2010
- 资助金额:
$ 22.3万 - 项目类别:
相似国自然基金
2023年(第四届)国际生物数学与医学应用研讨会
- 批准号:12342004
- 批准年份:2023
- 资助金额:8.00 万元
- 项目类别:专项项目
突变和修饰重塑蛋白质亚细胞定位的生物信息学研究
- 批准号:32370698
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于生物信息学的类风湿性关节炎患者衰弱预测模型的构建与验证
- 批准号:82301786
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于结构表征的蛋白质与长链非编码RNA相互作用预测的生物信息学方法研究
- 批准号:62373216
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
蛋白质降解决定因子的生物信息学筛选及其耐药突变的多组学分析研究
- 批准号:32300528
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Identification of Trichomonas vaginalis resistance targets to inform future drug development
确定阴道毛滴虫耐药靶标,为未来药物开发提供信息
- 批准号:
10462312 - 财政年份:2023
- 资助金额:
$ 22.3万 - 项目类别:
Serogroup 19 capsule maleability leading to vaccine failure
血清群 19 胶囊的雄性能力导致疫苗失败
- 批准号:
10723991 - 财政年份:2023
- 资助金额:
$ 22.3万 - 项目类别:
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency
治疗与年龄相关的皮肤干细胞缺乏症的多成分疗法
- 批准号:
10707346 - 财政年份:2022
- 资助金额:
$ 22.3万 - 项目类别:
Project 3: Multi-modal phenotypic Characterization of marmoset models of Late Onset Alzheimer's Disease
项目3:晚发性阿尔茨海默病狨猴模型的多模式表型表征
- 批准号:
10494777 - 财政年份:2022
- 资助金额:
$ 22.3万 - 项目类别:
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency
治疗与年龄相关的皮肤干细胞缺乏症的多成分疗法
- 批准号:
10494654 - 财政年份:2022
- 资助金额:
$ 22.3万 - 项目类别: